Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s13760-019-01259-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy, safety, and tolerability of adjunctive perampanel in the treatment of pediatric patients aged 4-18 years with epilepsy: A single-center, retrospective, observational real-world study.
Brain Dev
November 2024
Department of Pediatrics, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Electronic address:
Purpose: To observe the efficacy, safety, and tolerability of perampanel (PER) as add-on therapy in children aged 4-18 years with epilepsy in a real-world environment.
Methods: A single-center, retrospective, observational study was conducted at the First Affiliated Hospital of Fujian Medical University enrolling children with epilepsy aged 4-18 years who received PER as add-on therapy from January 2021 to November 2022 with 12 months of follow-up. Outcomes included 3-, 6- and 12-month retention, seizure freedom, responder rates, and adverse events (AEs) throughout follow-up.
Response to amoxicillin and perampanel in infantile Alexander disease.
Epilepsia Open
December 2024
Epilepsy Unit. Hospital de la Santa Creu i Sant Pau, Barcelona, UAB, Barcelona, Spain.
Article Synopsis
- - Type I Alexander disease is a severe neurological disorder that causes issues like seizures and developmental problems starting in early childhood, linked to a mutation in the GFAP gene.
- - Although there's no cure, some treatments like ceftriaxone and amoxicillin have shown mild symptomatic improvement in patients by affecting glutamate levels in the brain.
- - In a case study, a patient with severe irritability and seizures improved significantly after treatment with amoxicillin and perampanel, suggesting a potential role for glutamate-modulating drugs in treating this condition.
Effectiveness and safety of Perampanel in refractory status epilepticus: a case series.
Neurol Sci
October 2024
Department of Neurosciences, AOU "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
Introduction: Perampanel is a selective non-competitive antagonist of AMPA receptors, and the first agent of this class to become available for the treatment of epilepsy. It could be a useful tool for treatment of refractory status epilepticus (RSE).
Methods: We describe a series of eight RSE cases treated with Perampanel.
The Therapeutic Role of Perampanel in Treating Pediatric Patients With Dravet Syndrome: A Scoping Review.
Cureus
July 2024
Pediatric Neurology, King Abdulaziz University Hospital, Jeddah, SAU.
Sodium channelopathies are genetic disorders caused by mutations in genes, including sodium voltage-gated channel alpha subunit 1 (, that lead to several epilepsy syndromes. Traditional treatments with sodium channel blockers often have limited effectiveness and side effects. Dravet syndrome (DS), a severe epilepsy starting in infancy, presents significant treatment challenges.
View Article and Find Full Text PDFDeciphering the Complexities of Sodium Voltage-Gated Channel Alpha Subunit 1 (SCN1A) Mutation: A Case of Intractable Epilepsy in a Five-and-a-Half-Month-Old Male.
Cureus
July 2024
Pediatrics, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
If the sodium voltage-gated channel alpha subunit 1 () gene, which encodes Nav1.1 protein, undergoes pathological mutation, it results in a wide range of epileptic syndrome, including febrile seizure, genetic epilepsy with febrile seizure plus (GEFS+), and developmental and epileptic encephalopathy (DEE), including Dravet syndrome. We present the case of a five-and-a-half-month-old boy with gene-related epileptic seizures, starting as focal seizures and progressing to generalized tonic-clonic seizures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!